Active, not recruitingPhase 1NCT06206837
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Studying Rare malignant breast tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- vepdegestrant(drug)
- Enrollment
- 71 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2025
Study locations (20)
- Highlands Oncology, Fayetteville, Arkansas, United States
- Highlands Oncology, Rogers, Arkansas, United States
- Highlands Oncology Group, Springdale, Arkansas, United States
- Hoag Health Center Irvine, Irvine, California, United States
- Hoag Hospital Irvine, Irvine, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- Stanford Cancer Center, Palo Alto, California, United States
- Stanford Cancer Institute - Clinical Trials Office, Palo Alto, California, United States
- Stanford Women's Cancer Center, Palo Alto, California, United States
- UCSF Medical Center at Mission Bay, San Francisco, California, United States
- UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
- UCHealth Harmony, Fort Collins, Colorado, United States
- UCHealth Greeley Hospital, Greeley, Colorado, United States
- UCHealth - Medical Center of the Rockies, Loveland, Colorado, United States
- Smilow Cancer Hospital - Yale New Haven Health, New Haven, Connecticut, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06206837 on ClinicalTrials.govOther trials for Rare malignant breast tumor
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT06255808Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic SensorSeoul National University Hospital
- RECRUITINGNANCT06523452Laser Speckle Imaging During Breast ReconstructionRoyal Devon and Exeter NHS Foundation Trust
- RECRUITINGPHASE1NCT06239467First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerOnKure, Inc.
- ACTIVE NOT RECRUITINGNANCT06234488Multi-Institutional Transgender & Gender-Diverse Breast Cancer StudyMedical College of Wisconsin
- RECRUITINGPHASE2NCT05601440Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerCanadian Cancer Trials Group
- ENROLLING BY INVITATIONNANCT07206888Advanced Ultrasound Signal Processing of Suspicious Breast ImagesJohns Hopkins University
- ACTIVE NOT RECRUITINGPHASE3NCT01674140S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerSWOG Cancer Research Network
- ACTIVE NOT RECRUITINGPHASE3NCT01349322Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by SurgeryRadiation Therapy Oncology Group